UBS Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $31.7M | Sell |
1,130,221
-543,753
| -32% | -$14.5M | ﹤0.01% | 2107 |
|
|
2025
Q4 | $41.7M | Sell |
1,673,974
-322,026
| -16% | -$8.12M | 0.01% | 1814 |
|
|
2025
Q3 | $50.9M | Sell |
1,996,000
-57,520
| -3% | -$1.42M | 0.01% | 1607 |
|
|
2025
Q2 | $49.8M | Sell |
2,053,520
-672,954
| -25% | -$15.7M | 0.01% | 1529 |
|
|
2025
Q1 | $69.1M | Sell |
2,726,474
-1,041,346
| -28% | -$27.2M | 0.01% | 1186 |
|
|
2024
Q4 | $100M | Buy |
3,767,820
+210,404
| +6% | +$5.71M | 0.02% | 927 |
|
|
2024
Q3 | $103M | Buy |
3,557,416
+348,584
| +11% | +$10.2M | 0.02% | 704 |
|
|
2024
Q2 | $89.8M | Buy |
3,208,832
+410,298
| +15% | +$11.3M | 0.02% | 703 |
|
|
2024
Q1 | $77.7M | Sell |
2,798,534
-451,939
| -14% | -$12.5M | 0.02% | 776 |
|
|
2023
Q4 | $93.6M | Buy |
3,250,473
+1,570,641
| +93% | +$47.5M | 0.03% | 601 |
|
|
2023
Q3 | $55.7M | Buy |
1,679,832
+844,232
| +101% | +$29.9M | 0.02% | 778 |
|
|
2023
Q2 | $30.6M | Buy |
835,600
+342,800
| +70% | +$13.3M | 0.01% | 1130 |
|
|
2023
Q1 | $20.1M | Sell |
492,800
-379,000
| -43% | -$16.4M | 0.01% | 1387 |
|
|
2022
Q4 | $44.7M | Sell |
871,800
-828,300
| -49% | -$39.7M | 0.02% | 868 |
|
|
2022
Q3 | $74.4M | Buy |
1,700,100
+1,099,000
| +183% | +$53.4M | 0.03% | 531 |
|
|
2022
Q2 | $31.5M | Sell |
601,100
-316,300
| -34% | -$16.1M | 0.01% | 1036 |
|
|
2022
Q1 | $47.5M | Sell |
917,400
-1,342,312
| -59% | -$69.6M | 0.02% | 879 |
|
|
2021
Q4 | $133M | Buy |
2,259,712
+1,621,127
| +254% | +$80.3M | 0.04% | 483 |
|
|
2021
Q3 | $27.5M | Sell |
638,585
-246,803
| -28% | -$10.9M | 0.01% | 1254 |
|
|
2021
Q2 | $34.7M | Buy |
885,388
+32,503
| +4% | +$1.26M | 0.01% | 1070 |
|
|
2021
Q1 | $30.9M | Buy |
852,885
+514,185
| +152% | +$18.3M | 0.01% | 1144 |
|
|
2020
Q4 | $12.5M | Buy |
338,700
+309,715
| +1,069% | +$11.4M | ﹤0.01% | 1685 |
|
|
2020
Q3 | $1.01M | Sell |
28,985
-112,883
| -80% | -$3.96M | ﹤0.01% | 3629 |
|
|
2020
Q2 | $4.4M | Buy |
141,868
+22,450
| +19% | +$763K | ﹤0.01% | 2141 |
|
|
2020
Q1 | $3.7M | Sell |
119,418
-165,794
| -58% | -$5.65M | ﹤0.01% | 2194 |
|
|
2019
Q4 | $10.6M | Buy |
285,212
+251,168
| +738% | +$8.95M | ﹤0.01% | 1904 |
|
|
2019
Q3 | $1.16M | Sell |
34,044
-22,240
| -40% | -$809K | ﹤0.01% | 3831 |
|
|
2019
Q2 | $2.31M | Sell |
56,284
-120,577
| -68% | -$4.79M | ﹤0.01% | 3022 |
|
|
2019
Q1 | $7.13M | Sell |
176,861
-356,990
| -67% | -$14.3M | ﹤0.01% | 1932 |
|
|
2018
Q4 | $22.1M | Sell |
533,851
-108,035
| -17% | -$4.48M | 0.01% | 1017 |
|
|
2018
Q3 | $26.8M | Buy |
641,886
+277,846
| +76% | +$10.7M | 0.01% | 1015 |
|
|
2018
Q2 | $12.5M | Sell |
364,040
-180,878
| -33% | -$6.18M | 0.01% | 1551 |
|
|
2018
Q1 | $18.3M | Sell |
544,918
-138,496
| -20% | -$4.76M | 0.01% | 1227 |
|
|
2017
Q4 | $23.5M | Buy |
683,414
+346,450
| +103% | +$11.8M | 0.01% | 1087 |
|
|
2017
Q3 | $11.4M | Buy |
336,964
+275,832
| +451% | +$8.87M | 0.01% | 1505 |
|
|
2017
Q2 | $1.95M | Sell |
61,132
-264,621
| -81% | -$8.35M | ﹤0.01% | 3037 |
|
|
2017
Q1 | $10.6M | Sell |
325,753
-3,066,335
| -90% | -$96.7M | 0.01% | 1450 |
|
|
2016
Q4 | $105M | Buy |
3,392,088
+832,976
| +33% | +$25.4M | 0.06% | 325 |
|
|
2016
Q3 | $82.2M | Sell |
2,559,112
-303,763
| -11% | -$10.2M | 0.05% | 370 |
|
|
2016
Q2 | $95.6M | Sell |
2,862,875
-1,247,725
| -30% | -$39.8M | 0.06% | 318 |
|
|
2016
Q1 | $116M | Buy |
4,110,600
+709,031
| +21% | +$20.3M | 0.08% | 250 |
|
|
2015
Q4 | $104M | Sell |
3,401,569
-1,684,824
| -33% | -$53M | 0.07% | 286 |
|
|
2015
Q3 | $152M | Buy |
5,086,393
+4,252,679
| +510% | +$136M | 0.11% | 205 |
|
|
2015
Q2 | $26.5M | Buy |
833,714
+348,558
| +72% | +$11.4M | 0.02% | 803 |
|
|
2015
Q1 | $16M | Sell |
485,156
-1,858,795
| -79% | -$59.1M | 0.01% | 1114 |
|
|
2014
Q4 | $69.3M | Buy |
+2,343,951
| New | +$67.2M | 0.05% | 406 |
|
Other funds holding PFE
VCM
VPM
UBS Group's PFE Position: Q1 2026 in Review
UBS Group increased its Pfizer (PFE) stake by 4.8% in Q1 2026, buying an estimated $21.6M and bringing the position to 17,609,150 shares worth $494M. The position accounts for 0.07% of the portfolio, ranked #272.
UBS Group first reported a position in PFE in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.03B in Q4 2021. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- UBS Group held 17,609,150 shares of Pfizer worth $494M as of Q1 2026.
- UBS Group bought 811,135 Pfizer shares in Q1 2026, an estimated $21.6M.
- Pfizer made up 0.07% of UBS Group's portfolio in Q1 2026, its #272 holding.
- UBS Group first reported a position in Pfizer in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Pfizer position peaked at $1.03B in Q4 2021.
- 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.